Moderna and Merck announced a breakthrough in cancer treatment, confirming in a large phase-3 study that a personalized mRNA vaccine combined with established immunotherapy can significantly reduce the risk of recurrence and metastasis in patients with melanoma after surgery. (translated)
Moderna und Merck melden - Durchbruch bei erstem Krebs-Piks
